Juno Therapeutics, Inc., A Bristol-myers Squibb Company

This early-phase study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and calm the overactive immune system in severe autoimmune diseases like lupus, myositis, scleroderma, and rheumatoid arthritis. The goal is to see if it i…

This study tests a new treatment called arlocabtagene autoleucel (a CAR-T cell therapy) for adults with multiple myeloma that has come back or not responded to prior treatments. The therapy uses a patient's own immune cells, modified to target cancer cells. The study compares thi…

This early-stage study is testing a cell therapy called arlocabtagene autoleucel combined with other drugs (alnuctamab, mezigdomide, iberdomide, or elranatamab) in people with multiple myeloma that has returned or stopped responding to prior treatments. The main goals are to find…

This study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has returned or stopped responding to at least four prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The goal is to…

This early-stage study tests a new treatment called CC-97540, which uses a patient's own immune cells (CAR T cells) to target and calm the immune system in people with multiple sclerosis or myasthenia gravis. The main goal is to check safety and find the right dose. About 120 adu…

This study tests a one-time infusion of specially engineered immune cells (lisocabtagene maraleucel) as the first treatment for primary central nervous system lymphoma in 65 adults who are not eligible for a stem cell transplant. The goal is to see if this therapy can control the…

This early-stage trial tests a new treatment called BMS-986453 for people with multiple myeloma that has returned or stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to target two proteins on cancer cells, to try to control the dise…

This study tests a new treatment called CC-97540 for people with active lupus, including lupus nephritis, who haven't gotten better with standard medicines. The treatment uses specially engineered immune cells (CAR T cells) to target and destroy faulty immune cells causing the di…

This study tests a new treatment called BMS-986515 for people with severe autoimmune diseases that haven't improved with standard therapies. The treatment uses immune cells from healthy donors, modified to target and attack faulty immune cells. The main goal is to check safety an…